Email this article A structure of the antihypertensive drugs consumption in the population of several regions of the Russian Federation
- Authors: Blinkova P.R.1, Petrukhina I.K.1, Lebedev P.A.1, Ryazanova T.K.1, Gladunova E.P.1
-
Affiliations:
- Samara State Medical University
- Issue: Vol 22, No 4 (2022)
- Pages: 14-22
- Section: ORGANIZATION OF THE PHARMACEUTICAL BUSINESS
- URL: https://bakhtiniada.ru/2410-3764/article/view/120408
- DOI: https://doi.org/10.55531/2072-2354.2022.22.4.14-22
- ID: 120408
Cite item
Full Text
Abstract
Aim – to study the characteristics of the consumption of antihypertensive (AG) drugs in the population of several regions of the Russian Federation – the Samara region, the Nizhny Novgorod region and the Republic of Tatarstan.
Material and methods. The range of AG drugs sold in the retail pharmaceutical market of the Samara and Nizhny Novgorod regions and the Republic of Tatarstan was selected for the study. To manage the obtained data, we used several methods like structural, comparative, logical, predictive, retrospective, graphic, marketing analysis. The results were processed using the normalization method and methods of mathematical statistics.
Results. The monopreparations kept the main share of sales in each region: 90.22% in the Samara region, 90.85% in the Nizhny Novgorod region, and 93.72% in the Republic of Tatarstan). In 2021, the leaders in consumption were ACE inhibitors (28.41%, 26.61% and 32.7%, respectively in each region) and β-blockers (25.87%, 29.02% and 21.15%). In total, these two subgroups accounted for more than a half of all monopreparations sold, counted in packages. In the subgroup of fixed combinations, the angiotensin II receptor blockers + diuretic were the most popular, which account for 35.38%, 29.73% and 22.13% of drug sales in this subgroup in the Samara, Nizhny Novgorod regions and the Republic of Tatarstan, respectively. In the subgroup of combined antihypertensive drugs, the multicomponent fixed combinations were among the leaders (10.22%, 8.20%, 12.10%, respectively in each region), however, in the total consumption of antihypertensive drugs, they accounted for less than 1%.
Conclusion. This study revealed the features of the consumption of drugs prescribed for arterial hypertension in the Samara and Nizhny Novgorod regions, as well as in the Republic of Tatarstan in 2021. We identified the groups of antihypertensive drugs of most demand and found the leaders within these groups. It was established that there was a relationship between the volume of sales of antihypertensive medicines in physical terms (in packages) in the Samara region for the period 2017–2021 and the population of this region.
Full Text
##article.viewOnOriginalSite##About the authors
Polina R. Blinkova
Samara State Medical University
Author for correspondence.
Email: p.r.blinkova@samsmu.ru
ORCID iD: 0000-0002-8604-0729
Postgraduate Student of the Department of Management and Economics of Pharmacy
Russian Federation, SamaraIrina K. Petrukhina
Samara State Medical University
Email: i.k.petrukhina@samsmu.ru
ORCID iD: 0000-0001-6207-5575
PhD, Associate Professor, Dean of the Faculty of Pharmacy, Head of the Department of Management and Economics of Pharmacy
Russian Federation, SamaraPetr A. Lebedev
Samara State Medical University
Email: p.a.lebedev@samsmu.ru
ORCID iD: 0000-0003-3501-2354
PhD, Professor, Head of the Department of Therapy, Institute of Postgraduate Education
Russian Federation, SamaraTatyana K. Ryazanova
Samara State Medical University
Email: t.k.ryazanova@samsmu.ru
ORCID iD: 0000-0002-4581-8610
PhD, Director of the REC "Pharmacy", Associate Professor of the Department of Management and Economics of Pharmacy
Russian Federation, SamaraElena P. Gladunova
Samara State Medical University
Email: e.p.gladunova@samsmu.ru
ORCID iD: 0000-0001-5198-0393
PhD, Professor of the Department of Management and Economics of Pharmacy
Russian Federation, SamaraReferences
- Arterial hypertension in adults. Clinical guidelines 2020. Russian Journal of Cardiology. 2020;25(3):3786. (In Russ.). [Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786]. doi: 10.15829/1560-4071-2020-3-3786
- Kobalava ZhD, Konradi AO, Nedogoda SV. Russian of Cardiology position paper on 2018 Guidelines of the European Society of Cardiology / European Society of Arterial Hypertension for the management of arterial hypertension. Russian Jounal of Cardiology. 2018;23(12):131-142. (In Russ.). [Кобалава Ж.Д., Конради А.О., Недогода С.В. Меморандум экспертов Российского кардиологического общества по рекомендациям Европейского общества кардиологов / Европейского общества по артериальной гипертензии по лечению артериальной гипертензии 2018 г. Российский кардиологический журнал. 2018;23(12):131-142]. doi: 10.15829/1560-4071-2018-12-131-142
- Chazova IE, Zhernakova YuV. Clinical guidelines. Diagnosis and treatment of arterial hypertension. Systemic Hypertension. 2019;16(1):6-31. (In Russ.). [Чазова И.Е., Жернакова Ю.В. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019;16(1):6-31]. doi: 10.26442/2075082X.2019.1.190179
- ESC Guidelines on cardiovascular disease prevention in clinical practice. European Heart Journal. 2021;42:3227-3337. doi: 10.1093/eurheartj/ehab484
- Mortality by major causes of death. In: Russian Statistical Yearbook, 2021. [Смертность по основным классам причин смерти. В кн.: Российский статистический ежегодник 2021. (In Russ.). Available at: https://rosstat.gov.ru/storage/mediabank/Ejegodnik_2021.pdf
- World Health Organization. The top 10 causes of death. Geneva: WHO; 2020. https://www.who.int/ru/news-room/fact-sheets/detail/the-top-10-causes-of-death (9 December 2022).
- World Health Organization. WHO reveals leading causes of death and disability worldwide: 2000–2019. Geneva: WHO; 2020. https://www.who.int/news/item/09-12-2020-who-reveals-leading-causes-of-death-and-disability-worldwide-2000-2019 (9 December 2022).
- Statistics of morbidity and mortality from diseases of the circulatory system. (In Russ.). [Статистика заболеваемости и смертности от болезней системы кровообращения]. URL: https://www.who.int/ru/news/item/09-12-2020-who-reveals-leading-causes-of-death-and-disability-worldwide-2000-2019 (9 December 2022).
- "On approval of the standard for primary health care for primary arterial hypertension (hypertension)". Order of the Ministry of Health of the Russian Federation dated November 2012 No. 708n. (In Russ.). [«Об утверждении стандарта первичной медико-санитарной помощи при первичной артериальной гипертензии (гипертонической болезни)». Приказ Министерства здравоохранения Российской Федерации от 9 ноября 2012 г. № 708н]. Available at: https://minzdrav.gov.ru/documents/8390-prikaz-ministerstva-zdravoohraneniya-rossiyskoy-federatsii-ot-9-noyabrya-2012-g-708n-ob-utverzhdenii-standarta-pervichnoy-mediko-sanitarnoy-pomoschi-pri-pervichnoy-arterialnoy-gipertenzii-gipertonicheskoy-bolezni ( 09 November 2012).
- The fight against cardiovascular diseases in the Russian Federation. (In Russ.). [Борьба с сердечно-сосудистыми заболеваниями в РФ]. Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/046/710/original/FP_Bor'ba_s_serdechno-sosudistymi_zabolevaniyami.pdf?1565344425 (16 июля 2019).
- "On approval of the state program of the Russian Federation "Health Development"". Decree of the Government of the Russian Federation of December 26, 2017 No. 1640. (In Russ.). [«Об утверждении государственной программы Российской Федерации "Развитие здравоохранения"» . Постановление Правительства РФ от 26 декабря 2017 г. № 1640]. Available at: https://base.garant.ru/71848440
- "On Amendments to the State Program of the Russian Federation "Health Development"". Decree of the Government of the Russian Federation of March 31, 2021 No. 512. (In Russ.). «О внесении изменений в государственную программу Российской Федерации "Развитие здравоохранения"». Постановление Правительства РФ от 31 марта 2021 г. № 512]. Available at: https://www.garant.ru/products/ipo/prime/doc/400456274
- Mubarakshina OA, Somova MN, Batishcheva GA. Modern combination antihypertensive pharmacotherapy. Systemic Hypertension. 2018;15(4):30-33. (In Russ.). [Мубаракшина О.А., Сомова М.Н., Батищева Г.А. Современная комбинированная фармакотерапия артериальной гипертензии. Системные гипертензии. 2018;15(4):30-33]. doi: 10.26442/2075082X.2018.4.180149
- Morozova T.E. Combined antihypertensive therapy in the light of modern recommendations: strategy of one tablet. Systemic Hypertension. 2018;15(4):92-96. (In Russ.). [Морозова Т.Е. Комбинированная антигипертензивная терапия в свете современных рекомендаций: стратегия одной таблетки. Системные гипертензии. 2018;15(4):92-96]. doi: 10.26442/2075082X.2018.4.180110
- Chazova IE, Aksenova AV, Zhernakova YuV. "Polypill" conception in modern cardiology. Systemic Hypertension. 2018;15(4):6-7. (In Russ.). [Чазова И.Е., Аксенова А.В., Жернакова Ю.В. Концепция «полипилл» в современной кардиологии. Системные гипертензии. 2018;15 (4): 6-7]. doi: 10.26442/2075082X.2018.4.180116
- Belousov DYu, Cheberda AE. Pharmacoepidemiological studies: methodology and regulation. Kachestvennaya Klinicheskaya Praktika. 2017;(1):34-41. (In Russ.). [Белоусов Д.Ю., Чеберда А.Е. Фармакоэпидемиологические исследования: методология и регулирование. Качественная клиническая практика. 2017;(1):34-41].
- Rachina SA, Kozlov RS, Belkova YuA. Pharmacoepidemiology: from theory to practice. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2014;7(1):33-39. (In Russ.). [Рачина С.А., Козлов Р.С., Белькова Ю.А. Фармакоэпидемиология: от теоретических основ к практическому применению. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2014;7(1):33-39].
Supplementary files
